Bio-Techne Corp (NASDAQ:TECH) declared a quarterly dividend on Tuesday, October 31st, NASDAQ reports. Stockholders of record on Friday, November 10th will be given a dividend of 0.32 per share by the biotechnology company on Friday, November 24th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date is Thursday, November 9th.

Bio-Techne Corp (TECH) traded up 0.477% during trading on Wednesday, hitting $131.645. 25,683 shares of the stock were exchanged. Bio-Techne Corp has a 52 week low of $95.68 and a 52 week high of $132.57. The stock has a 50 day moving average of $122.81 and a 200-day moving average of $116.42. The stock has a market cap of $4.92 billion, a P/E ratio of 64.850 and a beta of 0.76.

Bio-Techne Corp (NASDAQ:TECH) last announced its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.02. Bio-Techne Corp had a net margin of 12.93% and a return on equity of 14.19%. The company had revenue of $144.61 million for the quarter, compared to analysts’ expectations of $142.37 million. During the same quarter in the previous year, the company earned $0.84 earnings per share. Bio-Techne Corp’s quarterly revenue was up 10.7% on a year-over-year basis. Equities analysts expect that Bio-Techne Corp will post $4.00 EPS for the current fiscal year.

In related news, Director Karen A. Holbrook sold 1,059 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $121.73, for a total transaction of $128,912.07. Following the sale, the director now owns 914 shares of the company’s stock, valued at $111,261.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 1,359 shares of company stock worth $164,632 in the last three months. 3.40% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Bio-Techne Corp (TECH) Plans Quarterly Dividend of $0.32” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at

Several equities analysts recently issued reports on TECH shares. Deutsche Bank AG boosted their price target on shares of Bio-Techne Corp from $130.00 to $132.00 and gave the company a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research raised shares of Bio-Techne Corp from a “hold” rating to a “buy” rating and set a $136.00 price objective on the stock in a research note on Wednesday, October 11th. BidaskClub raised shares of Bio-Techne Corp from a “hold” rating to a “buy” rating in a research note on Wednesday, August 23rd. Citigroup Inc. reissued a “buy” rating and set a $115.00 price objective (down previously from $125.00) on shares of Bio-Techne Corp in a research note on Tuesday, October 24th. Finally, Wells Fargo & Company started coverage on shares of Bio-Techne Corp in a research note on Thursday, July 13th. They set a “market perform” rating on the stock. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Bio-Techne Corp has a consensus rating of “Buy” and an average price target of $129.50.

About Bio-Techne Corp

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Dividend History for Bio-Techne Corp (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with's FREE daily email newsletter.